Long term effects of denufosol tetrasodium in patients with cystic fibrosis  by Ratjen, Felix et al.
Journal of Cystic Fibrosis 11 (2012) 539–549
www.elsevier.com/locate/jcfOriginal Article
Long term effects of denufosol tetrasodium in patients with cystic ﬁbrosis☆
Felix Ratjen a,⁎, Todd Durham b, Tomas Navratil c, Amy Schaberg d, Frank J. Accurso e,
Claire Wainwright f, Matthew Barnes g, Richard B. Moss h
the TIGER-2 Study Investigator Group
a Division of Respiratory Medicine, Department of Pediatrics, and Program in Physiology and Experimental Medicine, SickKids Research Institute,
The Hospital for Sick Children, and University of Toronto, Toronto, Canada
b Axio Research LLC, Seattle, WA, United States
c Parion Sciences, Inc., Durham, NC, United States
d Rho Inc, Chapel Hill, NC, United States
e Department of Pediatrics, University of Colorado Denver and Children's Hospital Colorado, United States
f Department of Respiratory Medicine, Queensland Children's Medical Research Institute, University of Queensland and Queensland Children's Respiratory Centre,
Royal Children's Hospital, Brisbane, Queensland, Australia
g TAB Clinical Trials, Cary, NC, United States
h Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, United States
26 March 2012; 8 May 2012; 12 May 2012
Available online 8 June 2012Abstract
Rationale: Denufosol stimulates chloride secretion independent of the chloride channel which is dysfunctional in cystic ﬁbrosis (CF) and therefore
has the potential to beneﬁt CF patients regardless of genotype.
Objectives: To assess the efﬁcacy of denufosol in CF patients with mild lung function impairment age 5 years and older.
Methods: This multicenter, randomized, parallel group double-blind placebo-controlled trial was conducted at 102 CF care centers in Australia,
Canada and the United States (NCT00625612) The active group (n=233) received 60 mg denufosol via inhalation three times daily The primary
efﬁcacy endpoint was change in FEV1 in liters from Day 0 to week 48.
Measurements and main results: 685 patients were screened for the study and 466 patients (233 in each group) were randomized to study treatment.
The adjusted mean change in FEV1was 40 mL for denufosol and 32 mL for placebo with a resulting treatment effect of 8 mL (95% CI −0.040,
0.056). The average rate of change in FEV1 percent of predicted over 0 to 48 weeks was −3.04% for placebo vs. −2.30 for denufosol (a difference
of 24% relative to placebo) among all patients. The incidence of pulmonary exacerbation was 26% vs. 21% for the placebo and denufosol groups
with no differences in the time to ﬁrst event. The study treatments were well tolerated and there was no evidence of systemic effects in any safety
parameter assessed.
Conclusions: In patients with CF treatment with denufosol for 48 weeks did not improve pulmonary function or reduce the incidence of pulmonary
exacerbations.
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Cystic fibrosis (CF) is an autosomal recessive disease caused
by mutations in the cystic fibrosis transmembrane regulator
(CFTR). CFTR functions as a chloride channel and is expressed
in epithelial membranes throughout multiple organ systems [1].
Pathological changes due to the underlying genetic defect are
evident in many organs, but lung disease accounts for most of the
morbidity andmortality in patients [2]. Defective chloride secretion
leads to reduced airway surface liquid, impaired mucociliary
clearance, and resultant airway infection and inflammation [3].
This process starts early and significant structural and functional
pulmonary changes have been documented in the first 6 years of
life [4–9].
Currently available interventions such as mucolytics and
antibiotics address the complications of CF lung disease and have
been demonstrated to improve lung function [10–15]. Recent
interest has focused on interventions which target the underlying
ion channel abnormality as highlighted by the promising results
for the CFTR potentiator ivacaftor in patients carrying at least one
copy of the G551D mutation [16]. If introduced early, therapies
directed against the underlying chloride channel defect could have
the potential to delay the progression of lung disease [14–16].
Denufosol tetrasodium is an investigational compound deliv-
ered via nebulization. Denufosol acts on P2Y receptors expressed
on the surface of airway epithelium to stimulate chloride secretion
via calcium activated chloride channels (CACCs), inhibit sodium
absorption via epithelial Na+ channels (ENAC), and stimulate
ciliary beat frequency; and thereby has the potential to benefit
patients independent of CFTR genotype [17].
Previous studies with denufosol have demonstrated its
potential to provide benefit to patients with CF. In a Phase 2
study [18] among patients with mild lung function impair-
ment, patients receiving denufosol treatment had significantly
better lung function after 28 days of treatment. Based on these
effects in patients with mild lung function impairment the
Phase III program for denufosol focused on this population of
CF patients. The positive findings were supported by the first
Phase 3 study (TIGER-1) which included a 24-week, placebo-
controlled, double-blind Phase III trial in 352 CF patients
where a moderate effect on forced expiratory volume in one
second (FEV1) (45 mL or 2% versus baseline) was observed
[19]. However, within this study these FEV1 results were not
corroborated with any statistically significant improvements
in other a priori defined secondary efficacy endpoints,
including pulmonary exacerbation rates, other measures of
lung function, hospitalization or illness (missed work/school)
rates, or quality of life.
The TIGER-1 study included a 24-week open-label extension
phase immediately following the 24-week double blind phase. In
this open-label extension, patients appeared to continue to improve
in the group originally assigned to denufosol, with a change in
inflection in the mean change in FEV1 for those patients whose
treatment was switched at Week 24 from placebo to denufosol.
This suggested that a longer treatment periodmight be necessary to
identify the time to maximum benefit of denufosol relative to
placebo on lung function. Based on these findings, the currentstudy (clinicaltrials.gov NCT00625612; TIGER-2) was designed
to assess the efficacy of treatment over 48 rather than 24 weeks in a
double blind trial. In addition, to increase power, the sample size
was increased from 350 to 450 patients compared to the previous
study, and patients with FEV1N110% predicted were excluded as
they were unlikely to improve lung function due to high baseline
values.2. Methods
2.1. Patient selection
Patients were eligible if they were at least 5 years of age, had a
confirmed diagnosis of CF and a FEV1 between 75% and 110% of
predicted normal for age, height and sex at screening [20,21].
Patients were required to be clinically stable, as evidenced by no
acute respiratory illnesses within 4 weeks of screening, and able to
demonstrate reproducible FEV1 measurements (±15%) on two
separate days [22]. All concomitant medications except hypertonic
saline were allowed during the study. Clinic visits for patients
taking inhaled antibiotics on a cyclical basis were scheduled so that
baseline and endpoint evaluations of lung function occurred at the
same relative time in each patient's cycle. The study protocol was
approved by the Cystic Fibrosis Foundation Therapeutics Devel-
opment Network Protocol Review Committee. An independent
data monitoring committee was chartered to prospectively evaluate
safety. The study was approved by the institutional review boards
of all participating centers and informed consent was obtained from
all study participants and/or guardians (including assent for minors
as appropriate).2.2. Study design
Subjects were enrolled from a total of 102 centers in the
United States (82), Canada (9), Australia/New Zealand (11)
over the period from Feb. 2008 to Oct. 2009. The study had a
48-week, placebo-controlled treatment period with scheduled
clinic visits at screening, Weeks 0, 4, 12, 24, 36 and 48. A web
based computer generated randomization sequence was used
stratified by study center assuring an allocation ratio of
denufosol to placebo was 1:1. The targeted study size was
450 subjects (225 per group). Study treatment was denufosol
tetrasodium inhalation solution, 60 mg (Inspire Pharmaceuti-
cals, Durham, NC) three times daily (TID) or placebo vehicle
(0.9% wt/vol saline) TID. The treatment was delivered via the
PARI LC Star Reusable Nebulizer (PARI Respiratory Equip-
ment Inc., Midlothian, VA) and the PARI PRONEB Ultra
Compressor (PARI Respiratory Equipment Inc.). The order of
concomitant treatments administration was prescribed in the
study protocol as follows: bronchodilator, dornase alfa, chest
physiotherapy or vest, study drug, and inhaled antibiotic. Use
of hypertonic saline was excluded. At selected sites, spontane-
ously expectorated sputum samples were collected for measur-
ing the concentration of denufosol pre-dose and at 5, 15, and
60 minutes post-dose during a Week 4 clinical visit.
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The primary efficacy endpoint was the change from baseline
to Week 48, defined as the Week 48 value or the last observation
carried forward, in FEV1 (liters). There were three key secondary
efficacy endpoints: (1) the rate of change in FEV1 percent of
predicted over the 48-week treatment period; (2) the time to first
pulmonary exacerbation requiring intravenous antibiotics to treat
at least one respiratory sign or symptom; and (3) change from
baseline to Week 48 endpoint in maximal mid-expiratory flow
(FEF25%–75% L/s). Three definitions of pulmonary exacerbation
were used: (1) the treatment with intravenous antibiotics for at
least one respiratory symptom; (2) the presence of 4 or more out
of 12 respiratory and systemic signs or symptoms; and (3) the
diagnosis by the investigators. Pulmonary function measure-
ments were obtained using standardized spirometry equipment
according to ATS standards (ATS/ERS 2005) and interpreted by
a centralized spirometry reading specialist (nSpire Health™,
Longmont, CO). Clinic spirometry was conducted after the study
drug had been withheld for at least 6 h and bronchodilator for at
least 2 h. Multiple exploratory efficacy endpoints were also
evaluated (clinicaltrials.gov NCT00625612). Safety was assessed
by reports of adverse events, clinical laboratory results, physical
examination results, and incidences of new pulmonary infections,
hospitalizations and changes from screening lung function.
2.4. Pulmonary pharmacokinetics
At selected sites, spontaneously expectorated sputum samples
were collected for measuring the concentration of denufosol pre-
dose and at 5, 15, and 60 min post-dose on Week 4. Samples
were collected in 50% EtOH solution containing EDTA, stored at
−20 °C and shipped into the central lab for analysis. Concentra-
tions of denufosol in sputum were determined using a liquid
chromatography tandem mass spectrometry (LC/MS/MS) by
Enthalpy Analytical, Durham, NC with a detection limit of
quantification of 1 ng/ml.
2.5. Statistical analysis
All analyses were pre-specified in the statistical analysis plan,
which was finalized prior to unblinding the study for analysis.
The primary analysis of efficacy was based on data from all
randomized patients (intent-to-treat population). To reduce the
variance of treatment effect estimates for the primary efficacy
analysis, baseline FEV1 was defined as the average of the two
FEV1 measurements obtained on separate days within a 4 week
period prior to randomization. Similarly, the Week 48 time point
was the average of two FEV1 measurements collected on 2
separate days after 48 weeks of treatment. The treatment effect
was assessed via an analysis of covariance (ANCOVA) model
with effects for treatment, pooled study site, and baseline FEV1.
Least squares (adjusted) means were estimated from the
ANCOVA model. The sample size was chosen so that the
study would have 90% power to detect a treatment difference in
change from baseline FEV1 of 0.075 L at 48 weeks. The analysis
of change from baseline FEF25–75% at Week 48 endpoint wasbased on an ANCOVA model similar to the analysis for the
primary endpoint. A proportional hazards model with effects for
treatment, pooled study site, and baseline FEV1 was used for the
analysis of the time to first pulmonary exacerbation. The rate of
change in FEV1 percent of predicted was analyzed using a
normality-based mixed effects model, including treatment,
pooled site, study week, baseline measurement as fixed effects,
and patient as a random effect, and using a spatial power
covariance structure.
The primary efficacy endpoint served as a gatekeeper for the
analyses of the key secondary efficacy endpoints. If there was a
statistically significant treatment effect for the primary efficacy
endpoint, the Hochberg procedure [23] was to be applied to the
three key secondary efficacy endpoints for the ITT population.
Therefore, the family-wise error rate was to be controlled at an
alpha level of 0.05 for the primary endpoint and three key
secondary efficacy endpoints. All other p-values for secondary
analyses were considered descriptive and exploratory in nature.
A priori subgroup analyses for the primary endpoint included
gender, age group, country, region, genotype, baseline status of
Pseudomonas aeruginosa infection, and baseline use of chronic
inhaled antibiotics, dornase alfa, or macrolides, and occurrence of
pulmonary exacerbation during the study. Overall interaction P-
values were based on the ANCOVAmodel with terms for pooled
study site, treatment, subgroup, baseline FEV1, and treatment-by-
subgroup interaction. Treatment effects (and 95% CI) for each
subgroup category were estimated using an ANCOVA model
with effects for pooled study site, treatment, and baseline FEV1.
Safety was evaluated by comparing the incidence of AEs
and changes in clinical laboratory tests, physical exam findings,
vital signs, weight, height, body mass index, electrocardio-
grams, and X-rays.
All analyses were performed using SASVersion 9.0 or higher.3. Results
3.1. Patients
A total of 685 patients were screened for the study and 466
patients (233 in each group) were randomized to study treatment
in the United States [384 patients (82%)], Canada [29 patients
(6%)], and Australia/New Zealand [53 patients (11%)] (Fig. 1).
The treatment groups were balanced with respect to demographic
and background characteristics (Table 1). On average, the
patients had mild lung function impairment, with a baseline
mean percent of predicted FEV1 of 90%. 40% of patients overall
(36% of placebo and 44% of denufosol subjects) were positive
for P. aeruginosa. 24% of patients had been hospitalized for a
pulmonary exacerbation in the previous year. The baseline con-
comitant medication use was similar in both treatment groups.
Study completion rates were high and similar between
treatment groups (82% for denufosol versus 83% for placebo).
The most common reason for study withdrawal was based on
patients' decision, associated with the time commitment required
for TID dosing. The rate of withdrawal due to adverse events was
6% in both groups. The average dosing compliance, estimated
SCREENED
N = 685
RANDOMIZED 
N = 466
ITT Population
N = 466
Placebo TID
N = 233
Denufosol 60mg TID
N = 233
COMPLETED
N = 193 (83%)
WITHDRAWN
N = 40 (17%)
Reasons for Withdrawal
Patient decision = 18
Physician decision = 3
Adverse Events = 14
%predicted FEV1<45% = 0 
Reasons for Withdrawal
Patient decision = 21
Physician decision = 3
Adverse Events = 15
% predicted FEV1<45% = 0
COMPLETED
N = 190 (82%)
WITHDRAWN
N = 43 (18%)
Fig. 1. Patient disposition. ITT = intent-to-treat; TID = three times daily.
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88% for denufosol.
3.2. Lung function
There was no benefit attributable to denufosol with respect to
the primary efficacy endpoint, change from baseline in FEV1 at
Week 48 endpoint. The adjusted mean change was 40 mL for
denufosol and 32 mL for placebo with a resulting treatment effect
of 8 mL (95% CI −0.040, 0.056; p-value=0.742; Table 2). The
mean response was similar for the two groups at all visits during
the placebo-controlled portion of the study (Fig. 2). In both
treatment groups, a decline in FEV1 in liters and percent of
predicted was apparent at Week 4 (Fig. 2). Furthermore, no
benefit in FEV1 change from baseline was apparent for any of the
pre-specified subgroups (Fig. 3), nor was any treatment-by-
subgroup interaction significant. Treatment differences were not
statistically significant for any other measure of lung function,
including two key secondary efficacy endpoints of change from
baseline FEF25%–75% at Week 48 endpoint and the rate of change
in FEV1 percent of predicted (Table 2).
The average rate of change in FEV1 percent of predicted over
0 to 48 weeks was −3.04% for placebo vs. −2.30 for denufosol
with a treatment difference (95% CI) of 0.73% (−1.01, 2.50).
The estimated treatment difference was 24% relative to placebo
among all patients. Given the significant decline in lung function
in both groups from baseline to theWeek 4 visit, we also analyzed
the rate of change including only the post-baseline values.
Excluding the baseline measure (Week 0), the rate of decline
was not significantly different, although a non-significant trend
favoring denufosol was observed (−2.32 for placebo vs. −1.40for denufosol; a relative difference of 40%). Although the mag-
nitude of the slope was affected by inclusion or exclusion of the
baseline value, the standard deviation of the slope was not.
3.3. Pulmonary exacerbations
The time to the first pulmonary exacerbation for any of the
three definitions did not differ between treatment groups (Fig. 4).
As evidenced by hazard ratios (95% CI) ranging from 0.7
(0.5, 1.1) for the primary definition (IV antibiotics to treat at least
one respiratory sign or symptom) to 0.9 (0.7, 1.2) for the other two
definitions of event, the risk of event was lower for denufosol-
treated subjects as for placebo. The overall incidence of pulmonary
exacerbation by the primary definition (IV antibiotics to treat at
least one respiratory sign or symptom) in the 48-week study period
was 26% vs. 21% for the placebo and denufosol groups,
respectively (Table 3). The frequency of exacerbations by the
two other definitions was higher in both groups (39% vs. 37% and
52% vs. 47%, respectively). There was no difference between the
groups with respect to the incidence or incidence density of
pulmonary exacerbation according to any definition.
3.4. Pulmonary pharmacokinetic profile of denufosol
Twenty patients participated in the sputum PK sub-study.
Eleven patients were randomized to receive denufosol, and nine
were randomized to receive placebo. The demographics for these
patients were similar to those of the Intent-to-Treat population
(data not shown). Levels of denufosol in sputum after termination
of inhalation were high (Cmax=393,480 ng/g±441,535 ng/g in
terms of mass of denufosol per mass of collected sputum,
Table 1
Demographic and baseline characteristics (ITT population).
Placebo
(N=233)
Denufosol, 60 mg
(N=233)
Total
(N=466)
Age, mean (SD), years 14.7 (8.91) 15.5 (8.89) 15.1 (8.90)
Age category, n (%)
5–11 years 99 (42%) 92 (39%) 191 (41%)
12–18 years 81 (35%) 73 (31%) 154 (33%)
≥19 years 53 (23%) 68 (29%) 121 (26%)
Male, n (%) 126 (54%) 128 (55%) 254 (55%)
White, n (%) 221 (95%) 224 (96%) 445 (95%)
CFTR genotype, n (%)
Δ F508 homozygous 120 (52%) 122 (52%) 242 (52%)
Δ F508 heterozygous 80 (34%) 80 (34%) 160 (34%)
Other/unknown 33 (14%) 31 (13%) 64 (14%)
BMI, mean (SD), kg/m2 19.42 (3.705) 19.64 (3.771) 19.53 (3.736)
Baseline FEV1 (L), mean (SD) 2.33 (0.961) 2.48 (1.019) 2.40 (0.992)
Baseline % of predicted FEV1, mean (SD) 88.7 (10.12) 90.7 (10.74) 89.7 (10.47)
Pseudomonas aeruginosa positive respiratory culture at baseline, n (%) 84 (36%) 102 (44%) 186 (40%)
History of hospitalization for exacerbation in prior year, n (%) 58 (25%) 54 (23%) 112 (24%)
Missed days of school/work in prior 28 days, n (%) 38 (16%) 29 (12%) 67 (14%)
Baseline use of concomitant medications:
Pancreatic enzymes, n (%) 209 (90%) 206 (88%) 415 (89%)
Bronchodilators, n (%) 196 (84%) 199 (85%) 395 (85%)
Dornase alfa, n (%) 176 (76%) 184 (79%) 360 (77%)
Chronic inhaled antibiotics, n (%) 86 (37%) 95 (41%) 181 (39%)
Chronic macrolides use, n (%) 80 (34%) 88 (38%) 168 (36%)
Chronic inhaled tobramycin use, n (%) 75 (32%) 83 (36%) 158 (34%)
Definition of abbreviations: ITT = intent-to-treat.
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sputum was short (T1/2=17.2 min±8.99 min).
3.5. Safety
The study treatments were well tolerated and there was no
evidence of systemic effects in any safety parameter assessed,
including clinical laboratories, adverse events, and anthropo-
morphic measures. Nearly all patients reported at least one
adverse event (see Table 4). The most commonly reportedTable 2
Lung function results (ITT population).
Statis
Primary endpoint: FEV1 (liters) change from baseline to Week 48 endpoint LS m
(SE)
Key secondary endpoint: FEV1 percent of predicted rate of change over
0–48 weeks (%/year)
Slope
SD
Key secondary endpoint: FEF25–75% (liters/s) change from baseline to Week
48 endpoint
LS m
(SE)
FEV1 percent of predicted (%) change from baseline to Week 48 endpoint LS m
(SE)
FEV1 percent of predicted rate of change over 4–48 weeks (%/year) Slope
SD
Values displayed for the change scores are the simple means (and their standard erro
model with effects for pooled site and baseline value, and the treatment effect (differ
rates of change are the slope estimate (and its standard error), the standard deviation
The rate of change was analyzed using a normality-based mixed effects model, inclu
and patient as a random effect, and using a spatial power covariance structure. P-va
treatment effect.
Definition of abbreviations: ITT = intent-to-treat; Week 48 endpoint = Week 48 val
a The treatment effect is the absolute difference (denufosol minus placebo) in sumadverse events occurred with similar frequency in the two groups
and were consistent with CF lung disease. The proportion of
patients experiencing at least a 20% decline in FEV1 percent of
predicted at any time during the study was similar for the two
treatments (15% for placebo vs. 9% for denufosol).
4. Discussion
This Phase 3 study was designed to assess the efficacy of
denufosol over an extended time period and in a larger sampletic Placebo
N=233
Denufosol, 60 mg
N=233
Treatment effect a
(95% CI)
P-
value
ean (SE) mean 0.032 (0.017)
0.032 (0.018)
0.040 (0.017)
0.039 (0.019)
0.008 (0.024)
(−0.040, 0.056)
0.742
(SE) −3.04 (0.627)
6.74
−2.30 (0.630)
5.58
0.73 (0.889)
(−1.01,2.50)
0.410
ean (SE) mean −0.018 (0.034)
−0.005 (0.035)
−0.034 (0.034)
−0.047 (0.034)
−0.017 (0.048)
(−0.111, 0.077)
0.728
ean (SE) mean −3.03 (0.553)
−2.95 (0.581)
−2.76 (0.553)
−2.84 (0.549)
0.27 (0.785)
(−1.27, 1.81)
0.731
(SE) −2.32 (0.698)
6.77
−1.40 (0.703)
5.17
0.92 (0.991)
(−1.02,2.86)
0.354
rs), the adjusted means (and their standard errors) obtained from an ANCOVA
ences in adjusted means) and its 95% confidence interval. Values displayed for
, and the treatment effect (difference in slopes) and its 95% confidence interval.
ding treatment, pooled site, study week, baseline measurement as fixed effects,
lues for all endpoints were obtained from the same models used to estimate the
ue, if present, and last observation carried forward otherwise.
mary statistics. Positive values favor denufosol.
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Fig. 2. Change from baseline in lung function by visit during the 48-week placebo-controlled period. Results are displayed for subjects with data at each time point.
Values displayed are the adjusted means (and their standard errors) from an ANCOVA model with effects for pooled site and baseline value. CFB = change from
baseline. (A) FEV1 (L); (B) FEV1 percent of predicted (%); (C) FEF25%–75% (L/s).
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observed on either lung function or pulmonary exacerbations
over the 48 week double blind placebo controlled treatment
period.Results for lung function differed from those obtained among
subjects treated with denufosol for 48 weeks (double-blind and
open-label periods) in the previous Phase III study [19]. The
mean change in FEV1 at 48 weeks for denufosol subjects was
ITT (N=466)
Gender
Male (N=254)
Female (N=212)
Age
5-11 Years (N=191)
12-18 Years (N=154)
≥19 Years (N=121)
Country
US (N=384)
Canada (N=29)
Australia/New Zealand (N=53)
Genotype
ΔF508 Homozygous (N=242) 
ΔF508 Heterozygous (N=160) 
Pa Status
Positive (N=186)
Non-positive (N=273)
Chronic inhaled antibiotics
Yes (N=181)
No (N=285)
Dornase alfa 
Yes (N=360)
No (N=106)
Chronic oral macrolides
Yes (N=168)
No (N=298)
-0.2 -0.1 0.0 0.1 0.2 0.3 0.4
Treatment Effect FEV1(95% CI; L)
Fig. 3. Forest plot of the treatment effect (and 95% CI) for the change from
baseline FEV1 at Week 48 endpoint for prespecified subgroups. Values displayed
are the treatment effects (differences in adjusted mean change from baseline) and
their 95% confidence intervals, estimated from an ANCOVA model with effects
for pooled site and baseline value. ITT = intent-to-treat.
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Fig. 4. Kaplan–Meier estimate of the time to first pulmonary exacerbation for
three definitions of exacerbation. (A) Treatment with IV antibiotics for at least
one respiratory sign or symptom. (B) Presence of at least 4 out of 12 signs and
symptoms. (C) Investigator-defined event. Hazard ratios, their 95% confidence
intervals, and P-values were obtained from a proportional hazards model with
effects for treatment, pooled study site, and baseline FEV1.
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observed in the present study among denufosol-treated subjects.
Although the mean change in FEV1 in the first 24 weeks for
placebo was similar in the TIGER-2 versus the TIGER1 1 trial
(−0.003 L vs. 0.003 L), the mean response among denufosol
subjects was quite different (0.001 L vs. 0.048 L). Interestingly, a
decline in FEV1 was observed in the first 4 weeks in both studies
which could represent regression to the mean in patients with
good baseline lung function who are enrolled into the study at a
point of maximal clinical stability and are much more likely to
worsen than improve their lung function.
There were no obvious differences in study design and/or
patient populations studied to explain these differences. Most
patients in the two studies had little or no impairment in lung
function (mean baseline FEV1 percent of predicted 90% vs.
92%). In the present study a greater percentage of patients was
hospitalized for pulmonary exacerbation in the previous year
(24% vs. 19%), which may reflect the slightly lower baseline
pulmonary function values.
Denufosol has been shown to be pharmacologically active in a
number of in vitro models where a robust increase in chloride
secretion, inhibition of sodium absorption and stimulation of the
ciliary beat frequency could be demonstrated in airway epithelial
cell cultures from CF patients [24]. The non-clinical evidence
would suggest that denufosol has the desirable pharmacological
activity targeting the defective ion transport and impaired ciliary
beat frequency underlying CF.
There are a number of possible explanations for the failure of
the study to support the in vitro data and earlier promising findings.
Although pharmacologically active in vitro, it is possible that
denufosol's short half-life in the pulmonary tissue observed in this
study contributed to the lack of clinical efficacy. Even though thetreatment was administered three times per day, the 17 minute
half-life determined in the pulmonary PK sub-study may have
been insufficient to result in a clinical benefit. The observed half
life differs from what was predicted from in vitro and ex vivo
studies [24]. Denufosol half-life was 25 h in ex vivo human CF
sputum, but reduced to 3 h in cultured, well differentiated human
nasal epithelial cells. These observations were consistent with a
postulated degradation mechanism via hydrolysis by extracellular
Table 3
Incidence and incidence density of pulmonary exacerbations (ITT population).
Randomization to Week 24 Randomization to Week 48
Placebo
N=233
Denufosol, 60 mg
N=233
P-value* Placebo
N=233
Denufosol, 60 mg
N=233
P-value*
PEx: IV antibiotics for at least one respiratory sign or symptom
Patients with≥1PEx, n(%) 31 (13%) 35 (15%) 0.624 61 (26%) 49 (21%) 0.169
Number of PEx per patient, n(%): 202 (87%) 199 (85%) 172 (74%) 185 (79%)
0 26 (11%) 31 (13%) 49 (21%) 36 (15%)
1 5 (2%) 2 (1%) 9 (4%) 7 (3%)
2 0 1 (b1%) 3 (1%) 4 (2%)
3 0 0 0 1 (b1%)
N3
Number of PEx/patient-year a 0.35 0.36 0.891 0.39 0.35 0.215
PEx: ≥4 out of 12 signs and symptoms
Patients with≥1PEx, n(%) 64 (27%) 63 (27%) 0.879 92 (39%) 87 (37%) 0.525
Number of PEx per patient, n(%): 169 (73%) 171 (73%) 141 (61%) 147 (63%)
0 46 (20%) 52 (22%) 56 (24%) 57 (24%)
1 14 (6%) 7 (3%) 23 (10%) 19 (8%)
2 4 (25) 3 (1%) 9 (4%) 7 (3%)
3 0 0 4 (2%) 3 (1%)
N3
Number of PEx/patient-year a 0.85 0.73 0.173 0.77 0.67 0.093
PEx: investigator-diagnosed
Patients with≥1PEx, n(%) 83 (36%) 82 (35%) 0.885 120 (52%) 110 (47%) 0.273
Number of PEx per patient, n(%): 150 (64%) 152 (65%) 113 (48%) 124 (53%)
0 60 (26%) 55 (24%) 64 (27%) 57 (24%)
1 17 (7%) 20 (9%) 35 (15%) 28 (12%)
2 4 (2%) 5 (2%) 12 (5%) 15 (6%)
3 2 (1%) 1 (b1%) 9 (4%) 9 (4%)
N3
Number of PEx/patient-year a 1.15 1.14 0.801 1.12 1.08 0.505
*P-values for the percent of patients with ≥1 PEx were obtained from the Cochran–Mantel–Haenszel chi squared test stratified by pooled study site. P-values for the
comparison of PEx/patient-year were obtained from a Poisson regression model with effects for pooled study site and baseline FEV1 value.
a Patient-years at risk does not include days during a pulmonary exacerbation.
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epithelia. Ectonucleotidase enzymes are up-regulated in CF airway
epithelia, thus potentially accounting for the increased hydrolysis
and shorter half-life of denufosol in CF airways [25].Table 4
Most common a adverse events (safety population b).
Pla
N=
Patients with any adverse events, n (%) 225
Cough 140
CF lung disorder (CF specific pulmonary exacerbation) 78
Headache 47
Nasal congestion 45
Pyrexia 57
Oropharyngeal pain 46
Lung disorder (non-CF specific pulmonary exacerbation) 45
Sputum increased 40
Rhinorrhea 43
Pseudomonas test positive 21
Pulmonary function test decreased 15
Fatigue 22
a Adverse events≥10% in either group.
b The safety population differed from the intent-to-treat population because two paGiven the short half-life and the implied short duration of
action therapy adherence may have been a key factor in the
study outcome. While the data based on returned vials suggest
high rates of adherence, the reliability of using vial counts as acebo Denufosol, 60 mg P-value
232 N=232
(97%) 222 (96%) 0.623
(60%) 137 (59%) 0.850
(34%) 75 (32%) 0.843
(20%) 58 (25%) 0.267
(19%) 54 (23%) 0.365
(25%) 50 (22%) 0.509
(20%) 47 (20%) N0.999
(19%) 38 (16%) 0.468
(17%) 37 (16%) 0.803
(19%) 31 (13%) 0.163
(9%) 26 (11%) 0.539
(6%) 26 (11%) 0.101
(9%) 23 (10%) 0.999
tients (one in each group) were randomized but were not treated with study drug.
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a 15 minute nebulization period per dose thrice daily over a 48-
week study duration, actual adherence rates may be significantly
lower based on the current knowledge of adherence to inhaled
drug therapies in CF patients [26,27].
A third potential explanation for the failure of this study is that
FEV1 over 1 year may not be as sensitive to change in a CF study
population with mild lung function impairment. This notion is
supported by other recent studies in which previously approved
therapies have failed to demonstrate a treatment benefit when
studied in patients with less advanced lung disease [28,29]. Most
drug development programs in CF have conducted their Phase III
program in patients with moderate disease as it is more likely to
improve lung function in this population. This poses a challenge
for treatments aiming to prevent lung function decline which will
be of highest benefit to patients prior to manifestation of
significant pulmonary damage.
Finally, it is possible that another measure of disease
progression could be better suited to capture treatment effects
in the studied population [8]. Identifying a more appropriate
endpoint is not without challenge. FEF25%–75%, a measure
which has been proposed as a more sensitive measure of lung
function in patients with early disease, would require even
more subjects than FEV1 due to its higher intra- and inter-
subject variability and did not demonstrate any treatment
benefits in this study. We did not include imaging techniques
or measures of airway inflammation that could potentially be
influenced by preventative treatment, but these outcome
measures have not yet been validated for Phase III trials in CF
patients.
In summary, the data from this trial do not suggest that patients
with mild lung function impairment will benefit from treatment
with denufosol 60 mg administered three times daily. Importantly,
the differing outcomes from two large studies of denufosol re-
inforce the importance of demonstrating efficacy in independent
studies. While the CFTR potentiator ivacaftor has recently been
shown to have remarkable benefits in CF patients carrying at least
one copy of the G551D mutations, these advances in the treatment
of CF lung disease have not fundamentally changed the long-term
prognosis for most patients. Despite the negative results of this
study, ion transport restoration independent of CFTR therefore
remains a viable therapeutic target for the treatment of CF lung
disease.
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